These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 11254577

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS, Ladehoff DK, Mehton NS, Noonan JS.
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-idiotype-induced, lipopolysaccharide-specific antibody response to Pseudomonas aeruginosa.
    Schreiber JR, Patawaran M, Tosi M, Lennon J, Pier GB.
    J Immunol; 1990 Feb 01; 144(3):1023-9. PubMed ID: 2104908
    [Abstract] [Full Text] [Related]

  • 8. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K, Goldberg JB, Pier GB.
    Infect Immun; 1995 Jan 01; 63(1):21-6. PubMed ID: 7528730
    [Abstract] [Full Text] [Related]

  • 9. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently.
    Schreiber JR, Cooper LJ, Diehn S, Dahlhauser PA, Tosi MF, Glass DD, Patawaran M, Greenspan NS.
    J Infect Dis; 1993 Jan 01; 167(1):221-6. PubMed ID: 8418172
    [Abstract] [Full Text] [Related]

  • 10. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T, Ito E, Nguyen VH, Haight M.
    Hum Vaccin Immunother; 2014 Jan 01; 10(10):2843-52. PubMed ID: 25483637
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB.
    J Immunol; 2008 Oct 01; 181(7):4965-75. PubMed ID: 18802100
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES, Lam JS.
    FEMS Microbiol Rev; 1997 Nov 01; 21(3):243-77. PubMed ID: 9451816
    [Abstract] [Full Text] [Related]

  • 18. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
    Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, Hoiby N, Fas SC, Lang AB.
    Antimicrob Agents Chemother; 2010 Jun 01; 54(6):2338-44. PubMed ID: 20308370
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.